Canvuparatide (MBX 2109)
Hypoparathyroidism
Phase 2Phase 2 (Avail trial) concluded May 2025; Phase 3 initiation planned for 2026.
Key Facts
Indication
Hypoparathyroidism
Phase
Phase 2
Status
Phase 2 (Avail trial) concluded May 2025; Phase 3 initiation planned for 2026.
Company
About MBX Biosciences
MBX Biosciences is a clinical-stage biotechnology company focused on transforming the treatment landscape for endocrine and metabolic disorders through its proprietary Precision Endocrine Peptide (PEP) platform. Its lead candidate, canvuparatide (MBX 2109), is a potential once-weekly PTH replacement therapy for hypoparathyroidism, having completed Phase 2 trials with Phase 3 initiation planned for 2026. The company's strategy leverages advanced chemical modifications, programmable prodrug technology, and fatty acylation to overcome the inherent limitations of native peptide hormones, positioning it to capture value in underserved, high-need patient populations.
View full company profileTherapeutic Areas
Other Hypoparathyroidism Drugs
| Drug | Company | Phase |
|---|---|---|
| Palopegteriparatide (TransCon PTH) | VISEN Pharmaceuticals | Phase 3 |
| Oral Long-Acting PTH Tablet | Opko Health | Preclinical |
| EB-612 | Extend Biosciences | Phase 2 |
| Hypoparathyroidism Program | Confo Therapeutics | Discovery |
| SEP-479 (PTH1R) | Septerna | Phase 2 |
| EB612 (oral PTH(1-34)) | Entera Bio | Phase 2 |
| Oral Long-Acting PTH | Entera Bio | Discovery/Preclinical |